作为一个致力于研究的世界级机构，建国大学除了建立负责推动教职员开展研究活动的研究和技术转移办事处外，还建立多个研究兴趣小组。因此，建国大学成为行业领导者的出色合作伙伴；目前，学校已与Gudpoin和Yamaha建立了合作研究关系。此外，建国国际学院还是海外许多知名高等教育机构在当地的领先合作伙伴，这充分证明了建国大学在领衔研究开发上作出的广泛努力。
BINUS UNIVERSITY 与广泛的国际高等教育机构及企业有着密切合作，该校学生有广大机遇参与到国际交流，实习，及各种交换生项目的机会。另外，我们的3+1提升项目，提供本科 学生有一年的社区发展研究，项目开发，及创业孵化参与经验积累机会。项目运作主要由BINUS Global Collaboration Center, BINUS Career, BINUS Entrepreneurship Center, the Research and Technology Transfer Office, and Teach For Indonesia。
BINUS UNIVERSITY researcher and Head of Department of Food Technology Dr Ingrid Surono is currently undertaking the first year of her research initiative on the potential use of probiotics as adjuvants for the management of diabetes mellitus and hypertension. The three-year research programme will aim to explore whether the regular consumption of probiotics can increase the absorption of nutrients by the body and thus any drugs consumed for the treatment of diabetes mellitus and hypertension.
Probiotics are live microorganisms which, when administered in regular amounts can provide health benefits for the host. The research programme is done in cooperation with the International Collaboration and Scientific Writing of RISTEK DIKTI in addition to Pajajaaran University, Gunma University, Japan, Maastricht University, Netherlands and PT Ultra Jaya Milk. Dr Surono utilised two probiotics, Lactobacillus plantarum IS-10506 and Enterococcus faecium IS-27256 — both isolated from Indonesian fermented buffalo milk — and were administered to test rabbits.
A total of 48 rabbits were divided into 6 groups; Group 1; the control group administered with the antidiabetic drug glibenclamide as the model for the diabetes mellitus drug; Group 2; pre-treated with Lactobacillus plantarum IS-10506 for 2 weeks before being administered with glibenclamide; and Group 3; pre-treated with Enterococcus faecium IS-27256 also for 2 weeks before being administered with glibenclamide. Group 4 was the control group administered with amlodipine which is commonly used to treat hypertension and Group 5 and 6 were treated similarly to Group 2 and 3 except the drug was changed to amlodipine.
Through the research, it is hoped that the probiotics will influence the gut microbiota — which plays a vital role in the body’s metabolic activities — of the test animals so that it will increase the absorption of the antidiabetic and antihypertensive drugs used. In the second and third year of the research programme, Dr Surono will move onto the clinical trial phase where she will implement her experimental methods on human test subjects.
Going forward, BINUS UNIVERSITY and Dr Surono’s research on probiotics will help to contribute to the field of functional foods and thus producing probiotic based functional foods which could help maintain many lifestyle diseases such as diabetes mellitus, hypertension and colon cancer among others.
